Targeting tumour necrosis factor in the treatment of rheumatoid arthritis

BioDrugs

Volumn 15, Issue 3, 2001, Pages 139-149

  Pearce, Glen J ^a   Chikanza, Lan C ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; LENERCEPT; METHOTREXATE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFUSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0035030724     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115030-00001     Document Type: Review

References (79)

1. Pincus T, Marcum SB, Callahan LF, et al. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J Rheumatol 1992; 19: 1874
2. Chikanza 1C, Jawed S, Naughton D, et al. Why do we need new treatments for rheumatoid arthritis? J Pharm Pharmacol 1998 ; 50: 357
3. Kwon B, Youn B-S, Kwon BS. Functions of newly identified members of the tumour necrosis factor receptor/ligand superfamilies in lymphocytes. Curr Opin Immunol 1999; 11: 340
4. Akira S, Hirano T, Taga T, et al. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEBJ 1990:70:2860
5. Jacob CO. Cytokines and anti-cytokines. Curr Opin Immunol 1989;2:249
6. Chikanza 1C, Grossmann AG. The neuroendocrine immune loop. Ballieres Clin Rheum 1996; 10: 199
7. Fong Y, Tracey J, Moldawer LL, et al. Antibodies to cachetin/tumour necrosis factor reduce interleukin-l and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170:1627
8. Buchan G, Barrett K, Turner M, et al. IL-1 and TNF mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol 1988; 73: 449
9. Butler D, Maini RN, Feldmann M, et al. Blockade of TNFa with chimeric anti-TNFa monoclonal antibody, cA.2 reduces (IL-6 and IL-8) release in rheumatoid arthritis PBMC cultures: a comparison with IL-1RA. Eur Cytokine Netwk 1995 ; 6:225
10. Haworth C, Brennan FM, Chantry D, et al. Expression of granulocyte macrophage colony stimulating factor in rheumatoid arthritis: regulation by tumour necrosis factor a. Eur J Immunol 1991; 21: 2575
11. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397
12. MacKay CR, Imhof BA. Cell adhesion in the immune system. Immunol Today 1993; 14: 99
13. Wallach D, Varfoolomeev EE, Malinin NL, et al. Tumour necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17:331
14. Seckinger P, Isaaz S, Dayer J-M. A human inhibitor of tumour necrosis factor alpha. J Exp Med 1988; 167: 1511
15. Olsson L, Lantaz S, Nilsson E, et al. Isolation and characterisation of a TNF binding protein from urine. Eur J Haematol 1989; 42: 270
16. Englemann H, Aderka D, Rubinstein M, et al. A tumour necrosis factor binding protein purified to homogeneity from human urine protects cells from tumour necrosis factor toxicity. J BiolChem 1989; 264: 11974
17. Dinarello CA. Biological basis for IL-1 in disease. Blood 1996; 87: 2095
18. Firestein GS, Boyle DL, Yu C, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994; 37: 644
19. Symons JA, Eastgate JA, Duff GW. Purification and characterisation of a novel soluble receptor for interleukin 1. J Exp Med 1991; 174: 1251
20. Chu CQ, Field M, Abney E, et al. Transforming growth factor l in rheumatoid synovial membrane and cartilage-pannus junction. Clin Exp Immunol 1991; 86: 380
21. Isomaki P, Luukainen R, Toivanen P, et al. The presence of IL-13 in the rheumatoid synovium and its anti-inflammatory effects on synovial fluid macrophages. Arthritis Rheum 1997; 39:1693
22. Chikanza 1C, Petrou P, Kingsley G, et al. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum 1992;35:1281
23. Harris Jr ED. Etiology and pathogenesis of rheumatoid arthritis. In: Kelley WN, Harris ED, Ruddy S, et al., editors. Textbook of rheumatology. 4th ed. Philadelphia: WB Saunders, 1993:833
24. Tak P, Zvaifler NJ, Green DR, et al. Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today 1999; 21: 78
25. Sen M, Lauterbach K, EI-Gabalawy H, et al. Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sei USA 2000; 97: 2791
26. Bancherau J, de Paoli P, Valle A, et al. Long-term human B-cell lines dependent on interleukin-4 and antibody to CD40. Science 1991;251:70
27. Wahl SM. Transforming growth factor : the good the bad and the ugly. J Exp Med 1994; 180: 1587
28. Elliot MJ, Maini RN, Feldman M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor. Arthritis Rheum 1993; 36: 1681
29. Elliot MJ, Mainini RN, Feldmann M, et al. Randomised double blind comparison of chimeric monoclonal antibody to tumour necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105
30. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Immunol 2000; 51: 207
31. Maini RN, Breedveld FC, Kalden JR. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor monoclonal antibody combined with low dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552
32. Kavanaugh A, StClair EW, McCune WJ, et al. Chimeric antitumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27: 841
33. Lorenz HM, Grunke M, Hieronymus T, et al. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2. J Rheumatol 2000; 27: 304
34. Ohshima S, Mima T, Sasai M, et al. Tumour necrosis factor alpha (TNF-alpha) interferes with Fas mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anu'-TNF-alpha therapy for RA. Cytokine 2000; 12:281
35. Lipsky PE, van der Heijde DMFM, St Clair MW, et al. lnfliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594
36. Maini RV, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor-a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a random phase in trial. Lancet 1999; 354: 1932
37. Targan SR, Hanauer SB, von Deventer SJH, et al. A short term study of chimeric monoclonal antibody cA2 to tumour necrosis factor-a for Crohn's disease. N Engl J Med 1997;337:1029
38. Lorenz HM, Hieronymus T, Grunke M, et al. In vivo blockade of TNF-a in patients with rheumatoid arthritis: indication for tachyphylaxis in long term ex vivo and in vitro effects after repeated in fusion of chimeric monoclonal antibody cA2. Arthritis Rheum 1996; 39: 1297
39. Celltech. CDP 870 for rheumatoid arthritis. Media release [1 page]. Available from URL: http://www.celltech.co.uk [Accessed 1999 Mar 3]
40. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human antibody (CDP571 ) in rheumatoid arthritis. Br J Rheumatol 1996; 34: 334
41. Choy EHS, Rankin ECC, Kassimos D, et al. The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 2310
42. Rau R, Saunder O, den Breeder A, et al. Long-term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:S55
43. Rau R, Herborn G, Sander D, et al. Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographie disease progression in rheumatoid arthritis. Arthritis Rheum 1999; 42: S400
44. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141
45. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of entracept, a recombinant tumour necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253
46. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586
47. Feldman M, Elliot MJ, Moody JN, et al. Anti-tumour necrosis factor therapy of rheumatoid arthritis. Adv Immunol 1997; 64:283
48. Edwards III CK. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann Rheum Dis 1999; 58: 173
49. Moreland LW, McCabe DP, Caldwell JR, et al. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J Rheumatol 2000; 27: 601
50. Chikanza 1C, Jawed S, Blake DR, et al. Treatment of patients with RA with RP73401 phosphodiesterase type 4 inhibitor. Arthritis Rheum 1996; 39: S282
51. Kisich KO, Malone RW, Feldstein PA, et al. Specific inhibition of TNF-ot expression by in vivo ribozyme treatment, i Immunol 1999; 163: 2008
52. Mohler KM, Torrance DS, Smith ÇA, et al. Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1996; 151: 1548
53. Mohan N, Edwards ET, Cupps TR, et al. Demyelination diagnosed during etanercept (TNF fusion protein) therapy. Arthritis Rheum 2000; 43 (Suppl.): 228
54. Food and Drug Administration. Wyeth-Ayerst, Immunex. Important drug warning. Available from URL: http://www.fda.gov/medwatch/safety/2000/enbrell.pdf [Accessed 2001 Mar 12]
55. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following antiTNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521
56. Perkins DJ, St Clair EW, Misukonis MA, et al. Reduction of NOS2 over-expression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). Arthritis Rheum 1998; 41: 2205
57. Ohshima S, Saeki Y, Mima T, et al. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol 1999; 19: 305
58. Neve R, Kissonerghis M, Clark J, et al. Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist. Cytokine 1996; 8: 365
59. Le CH, Nicholson G, Morales A, et al. Suppression of collagen induced arthritis through adenovirus mediated transfer of a modified tumour necrosis factor receptor gene. Arthritis Rheum 1997; 40: 1662
60. Quattrocchi E, Walmesley M, Browne K, et al. Paradoxical effects of blockade of TNF activity in murine collagen induced arthritis. J Immunol 1999; 163: 1000
61. Cheraajovsky Y. Systemic gene therapy for arthritis. In: Evans C, Robbins RD, editors. Discovery, development and evaluation of new anti-rheumatic drugs. Vol. 35. Barcelona: Prous Science, 1999: 361
62. Edwards III CK, Chipala ES, Dinarello ÇA, et al. Clinical and histopathological characterisation of arthritis in male and female tumour necrosis factor a knockout (TNFa-/-) and membrane bound TNFa transgenic (TNFTgA86) mice injected with mycoplasma pulmons or mycoplasma athritidis. Arthritis Rheum 1999;42:S120
63. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999; 26: 717
64. Thiel M, Bardenheuer H, Poch G, et al. Pentoxyfylline does not act via adenosine receptors in the inhibition of the Superoxide anion production of human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1991; 180: 53
65. Beavo JA, Reisfeld DH. Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol Sei 1990; 11: 150
66. Maksymowych WP, Avina-Zubieta A, Luong MH, et al. An open study of pentoxyfylline in the treatment of severe refractory RA. J Rheumatol 1995; 22: 625
67. Suttorp N, Weber U, Welsch T, et al. Role of phosphodiesterase in the regulation of endothelial permeability in vitro. J Clin Invest 1993; 91: 1421
68. Semmler JH, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses TNFa production by human mononuclear cells. Int J Immunopharmacol 1993; 15: 409
69. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in regulation of inflammatory protein biosynthesis. Nature 1994; 372: 739
70. Sirko S, Schindler R, Doyle MJ, et al. Transcription, translation, and secretion of interleukin 1 and tumour necrosis factor: effects of tebeufelone, a dual cyclooxygenase/5-lipoooxygenase inhibitor. Eur J Immunol 1991 ; 21: 242
71. Udalova 1A, Knight JC, Vidai V, et al. Complex NF-KB interactions at the distal tumour necrosis factor promoter region in human monocytes. J Biol Chem 1998; 273: 21178
72. Rhoades KL, Golub JH, Economou JS. The regulation of the human tumour necrosis factor a promoter region in macrophage, T-cell and B-cell lines. J Biol Chem 1992; 267: 22102
73. Leitman DC, Ribeiro AC, Maccow ER, et al. Identification of a tumour necrosis factor responsive element in the tumour necrosis factor alpha gene. J Biol Chem 1991 ; 266: 9343
74. Pope RM, Leutz A, Ness SA. C/EBP regulation of the tumour necrosis factor a gene. J Clin Invest 1994; 94: 1449
75. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kB activity. Annu Rev Immunol 2000; 18:621
76. Foxwell B, Browne K, Bundeson J, et al. Efficient adenoviral infection with 1KB reveals that macrophage tumour necrosis factor a production in rheumatoid arthritis is NF-KB dependent. Proc Natl Acad Sei USA 1998; 95: 8211
77. Tomita T, Takeuchi E, Tomita N, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42: 2532
78. May MJ, D'Acquisto FD, Madge LA, et al. Selective inhibition of NF-Kb activation by a peptide that blocks the interaction of NEMO with the DcB kinase complex. Science 2000; 289:1550
79. Gao YH, Lecker S, Post MJ, et al. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest 2000; 106:439